Biocon has put the development of its diabetes drug on the fast track by teaming up with US-based biopharma player Amylin Pharmaceuticals. The companies have entered into an exclusive co-development and marketing partnership for a peptide hybrid or phybrid. This phybrid will combine properties of two peptides — essentially small proteins — into one molecule to treat diabetes. For instance, this bi-functionality could lower glucose levels as well as induce weight loss.
Against using single properties on their own, this technology is likely to give a differentiated clinical outcome by enabling the interplay of two peptides with dual benefits (like lower sugar level and weight loss).
Amylin Pharmaceuticals has been a front-runner in the field of peptide therapeutics and a leader in the diabetes market. The Kiran Mazumdar Shaw-led Biocon will in turn bring its recombinant knowledge, large-scale manufacturing and low-cost pre-clinical and clinical development to the partnership.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: